POZEN, Inc. (POZN)

FDA concerns about tox have been addressed according to publicly available data. Given that the concern was addressed and seemingly negated, it would seem approval is right around the corner.





Word of Caution: You can never predict how the FDA will react. I recall a legal case I did some research on involving BMS a few years back where BMS hyping product and the whole world thought was a "gimme" only to have it rejected. remember, only the FDA knows what the FDA is thinking... though sometimes i not even sure they know exactly what they are thinking!





Assuming approval is granted, parntership with GSK is a HUGE bonus. GSK sales force has experience in this therapeutic area. Easy transition, easy ins with current trusted physicians... assuming no negative stories come up in post marketing surviellence look for this stock to rise signficantly from current prices. Good news is these prices are a steal with the pps taking a beating, probably due it being a speculative stock and big investors cashing out trying to meet margin calls elsewhere.





pain is huge area in healthcare, but can be a bit risky as well. however, from the data i've seen i think there is promise in the product. beyond a few years i have my doubts on the leadership of the company, but in a few years who knows what will be and i'll reevaluate....